Clinical studies in prostate cancer show that increased expression of IGFBP5 improves the efficacy of radiotherapy for localized prostate cancer, and in vitro IGFBP5 overexpression induced G2/M phase cell cycle arrest via PI3K/AKT signaling (87). This evidence concerns the gene AKT1 and prostate carcinoma.